Relmada Therapeutics Inc
RLMD
Company Profile
Business description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Contact
2222 Ponce de Leon Boulevard
Floor 3
Coral GablesFL33134
USAT: +1 786 629-1376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,169.90 | 89.30 | -0.96% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,556.28 | 411.81 | -1.47% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 52,923.12 | 452.48 | -0.85% |
| NZX 50 Index | 13,413.98 | 65.37 | 0.49% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,875.70 | 79.40 | -0.89% |
| SSE Composite Index | 4,104.10 | 53.88 | -1.30% |